Drug Profile
Balstilimab - Agenus/Ludwig Institute for Cancer Research
Alternative Names: AGEN-2034; BAL - Agenus/Ludwig Institute for Cancer Research; RebmAb-700Latest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator Agenus; Ludwig Institute for Cancer Research
- Developer Agenus; Betta Pharmaceuticals Co Ltd; Oxford BioTherapeutics; Rottapharm Biotech
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cervical cancer
- Phase II/III Solid tumours
- Phase II Adenocarcinoma; Colorectal cancer; Haemangiosarcoma; Lymphoma; Oropharyngeal cancer; Renal cell carcinoma; Soft tissue sarcoma
- Phase I/II Triple negative breast cancer
- Phase I Adenoid cystic carcinoma
Most Recent Events
- 20 Mar 2024 Immune Oncology Research Institute plans a phase II trial for Non-small cell lung cancer (First line therapy, Metastatic disease, Combination therapy, Late-stage disease) in Armenia (IV), in May 2024 (NCT06322108, IMMONC0008)
- 08 Mar 2024 Weill Medical College of Cornell University in collaboration with plans a phase II trial for Colorectal cancer (Metastatic disease, Combination therapy) in USA (IV, Infusion) (NCT06300463)
- 01 Feb 2024 Phase-II clinical trials in Adenocarcinoma (Combination therapy, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT06251973)